1. Pink Sheet

EMA Consults On SmPC Content Relating To Pharmacodynamic Properties

 
• By Vibha Sharma

The European Medicines Agency is consulting on how drug assessors can ensure that information submitted by sponsors on their drug’s pharmacodynamic properties is limited to what is relevant to a prescriber.

Person reading patient instruction leaflet at the tablets and glass of water
SmPC forms the basis for the safe and effective use of a medicine by health care providers • Source: Shutterstock

The European Medicines Agency is inviting stakeholder feedback on a draft guideline that sponsors can refer to when preparing a summary of product characteristics (SmPC) document for regulatory review to ascertain what information to include on a drug’s pharmacodynamic properties.

While the draft guideline is meant for drug assessors who review SmPC documents submitted in relation to medicines evaluated via...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

US FDA Advisory Committee Supports Vaccine Safety, Scrutinizes AE Reporting Quality

 
• By Sue Sutter

The Pediatric Advisory Committee supported routine safety monitoring for three vaccines and 21 drugs, but the panel’s consumer representative said adverse event reporting needs improvement and FDA literature reviews should include lawsuits as well as social media.

US FDA Will Not Pull Teva And MSN Hetlioz ANDAs, Rejects Vanda Citizen Petitions

 
• By Dean Rudge

The FDA concluded that generic tasimelteon products held by Teva and MSN Labs meet all statutory bioequivalence requirements and there was no “mistake” or untrue statement in the original ANDA approvals.

AI And Inertia: The Disruptors Keeping EU Regulators Awake At Night

 
• By Francesca Bruce

Data is “the new oil,” but its use will challenge regulators, while inertia is the biggest disrupter of all for European regulators, according to European Medicines Agency chiefs past and present.